Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper - Basic Science

3O - Efficacy of the triple combination of Estrogen Receptor, CDK4/6 and PI3K pathway inhibitors in ex-vivo models of breast cancer

Date

21 Sep 2020

Session

Proffered Paper - Basic Science

Presenters

Anna Diana

Citation

Annals of Oncology (2020) 31 (suppl_4): S245-S259. 10.1016/annonc/annonc265

Authors

A. Diana1, C.M. Della Corte1, F. Carlino1, V. Ciaramella1, E. Franzese1, S. Centonze1, C. Trovato1, I. Vassallo1, F. Iovino2, E. Procaccini3, F. Ciardiello1, F. Morgillo1, M. Orditura1

Author affiliations

  • 1 Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, 80131 - Napoli/IT
  • 2 Cardiothoracic Surgery, Università degli Studi della Campania Luigi Vanvitelli, 80131 - Napoli/IT
  • 3 Breast Unit, Università degli Studi della Campania Luigi Vanvitelli, 80131 - Napoli/IT
More

Resources

Login to access the resources on OncologyPRO.

Abstract 3O

Background

Activation of the Phosphatidylinositol 3-kinase (PI3K) pathway is common in Estrogen receptor (ER)-positive breast cancer (BC) and it has been associated with resistance to endocrine therapies (ET). The crosstalk between the Cyclin-dependent kinase 4/6 (CDK4/6) and PI3K pathways represents a strong rationale for co-targeting both axes to inhibit tumor growth. Moreover, combined treatment with PI3K and CDK4/6 inhibitors has been shown to overcome CDK4/6 inhibitor resistance in BC cells. We investigated the triple combination of ER, CDK4/6, and PI3K pathway inhibitors in ex vivo BC models as a novel strategy to overcome endocrine and CDK4/6-resistance.

Methods

We generated 25 ex vivo three dimensional spheroid culture models (organoids) from ER-positive BC samples, obtained from patients at surgery. After 5 days of treatment, we investigated anti-proliferative effects by MTT assay in these models with single agents, dual and triple combinations of Fulvestrant (F), Palbociclib (P) and Taselisib (T) as models of ET, CDK 4/6 and PI3K pathway inhibitors, respectively. We are also performing NGS analysis of both organoids and surgical samples to investigate predictive genomic biomarkers.

Results

Our results demonstrated that combination of F, P and T had a synergistic effect on the inhibition of spheroids proliferation in ≈30% of the examined samples compared to single drug treatments. Two subgroups of samples with different behavior were identified: one group showed no effect after single or triple treatment with only ≈15% reduction in cell viability (probably resistant) while the other group exhibited greater sensitivity to treatments (e.g. lobular histotype). Ongoing NGS analysis including a full panel of cancer-related genes, such as genes involved in CDK and PI3K pathways resistance. We will analyze concordance between surgical samples and ex vivo models in terms of genomic features and we will explore predictive role of genomic alterations.

Conclusions

The results showed an encouraging activity of the triple combination of ER, CDK4/6, and PI3K pathway inhibitors in ex vivo models of ER-positive BC. The different effect of the treatments could suggest a correlation between mutation setting and individual response.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

University of Campania.

Funding

Pfizer.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings